PedAM
Pediatric Disease Annotations & Medicines
| Disease | cystic fibrosis |
| Phenotype | C0267963|exocrine pancreatic insufficiency |
| Sentences | 7 |
| PubMedID- 21342076 | Research design and methods: patients with exocrine pancreatic insufficiency due to cystic fibrosis (cf) who had previously taken high doses of pancreatic enzymes received pancreatin 40,000 capsules (creon 40,000 minimicrospheres, abbott gmbh, hanover, germany) as part of their normal treatment for up to 2 years. |
| PubMedID- 25050848 | Long-term treatment (up to 12 months) of infants with exocrine pancreatic insufficiency owing to cystic fibrosis with zenpep was well tolerated and associated with improved growth parameters. |
| PubMedID- 21632288 | Efficacy and safety of pancreaze(r) for treatment of exocrine pancreatic insufficiency due to cystic fibrosis. |
| PubMedID- 20171415 | Background: pancreatic enzyme replacement therapy (pert) is essential for maintaining adequate nutrition in children with exocrine pancreatic insufficiency (epi) due to cystic fibrosis (cf). |
| PubMedID- 21086085 | exocrine pancreatic insufficiency (epi) is associated with conditions including cystic fibrosis (cf), chronic pancreatitis (cp), and pancreatic surgery (ps). |
| PubMedID- 25066363 | Safety and efficacy of creon(r) micro in children with exocrine pancreatic insufficiency due to cystic fibrosis. |
| PubMedID- 20441244 | Safety and tolerability of a new formulation of pancrelipase delayed-release capsules (creon) in children under seven years of age with exocrine pancreatic insufficiency due to cystic fibrosis: an open-label, multicentre, single-treatment-arm study. |
Page: 1